Omega-3 Fatty Acid

This page covers all Omega-3 Fatty Acid drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Hepatic triglyceride synthesis pathway, Multiple targets including triglyceride metabolism and inflammatory pathways.

Targets

Hepatic triglyceride synthesis pathway · Multiple targets including triglyceride metabolism and inflammatory pathways

Marketed (2)

• Epanova · AstraZeneca · Metabolic
• Omacor® · Hospital Universitari Vall d'Hebron Research Institute · Cardiovascular
  Omacor is a prescription omega-3 fatty acid formulation that reduces triglyceride levels by decreasing hepatic triglyceride synthesis and increasing fatty acid oxidation.

Phase 3 pipeline (3)

• Icosapent ethyl (IPE) · Estudios Clínicos Latino América · Cardiovascular
  Icosapent ethyl is a purified ethyl ester of eicosapentaenoic acid (EPA) that reduces triglyceride levels and modulates lipid metabolism.
• Eicosapentaenoic acid gastro-resistant capsules · S.L.A. Pharma AG · Cardiovascular
  Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that reduces triglycerides and modulates inflammatory pathways in cardiovascular disease.
• AMR101 · Massachusetts General Hospital · Cardiovascular
  AMR101 is a high-purity eicosapentaenoic acid (EPA) that reduces triglycerides by inhibiting hepatic triglyceride synthesis and enhancing fatty acid oxidation.

Patent intelligence

• omega 3 fatty acid patent landscape — aggregated cliff calendar, attackable patents, originator estates